Cargando…

Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer

PARP inhibitors have been widely tested in clinical trials, especially for the treatment of breast cancer and ovarian cancer, and were shown to be highly successful. Because PARP primarily functions in sensing and repairing DNA strand breaks, the therapeutic effect of PARP inhibition is generally be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Dong, Liu, Zhaojian, Xu, Xiuhua, Liu, Qiao, Zhang, Xiyu, Kong, Beihua, Wei, Jian-Jun, Gong, Yaoqin, Shao, Changshun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006521/ https://www.ncbi.nlm.nih.gov/pubmed/29684820 http://dx.doi.org/10.1016/j.redox.2018.03.016

Ejemplares similares

Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition
por: Hou, Dong, et al.
Publicado: (2017)

Mitochondrial superoxide contributes to oxidative stress exacerbated by DNA damage response in RAD51-depleted ovarian cancer cells
por: Xu, Limei, et al.
Publicado: (2020)

Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51
por: Wang, Bingliang, et al.
Publicado: (2015)

Resveratrol sequentially induces replication and oxidative stresses to drive p53-CXCR2 mediated cellular senescence in cancer cells
por: Li, Boxuan, et al.
Publicado: (2017)

Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation
por: Zhang, Xiyu, et al.
Publicado: (2015)

MYC-regulated pseudogene HMGA1P6 promotes ovarian cancer malignancy via augmenting the oncogenic HMGA1/2
por: Tian, Xiaoxue, et al.
Publicado: (2020)

Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2
por: Wang, Shourong, et al.
Publicado: (2021)

Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence
por: Xu, Xiuhua, et al.
Publicado: (2019)

Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12
por: Wang, Zixiang, et al.
Publicado: (2022)

miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma
por: Dong, Ruifen, et al.
Publicado: (2014)

Autophagy Contributes to the Maintenance of Genomic Integrity by Reducing Oxidative Stress
por: Bu, Wenqing, et al.
Publicado: (2020)

GSH-dependent antioxidant defense contributes to the acclimation of colon cancer cells to acidic microenvironment
por: Zhao, Minnan, et al.
Publicado: (2016)

Disrupted mitochondrial homeostasis coupled with mitotic arrest generates antineoplastic oxidative stress
por: Hao, Xiaohe, et al.
Publicado: (2021)

Lack of interferon-γ receptor results in a microenvironment favorable for intestinal tumorigenesis
por: Zhang, Caibo, et al.
Publicado: (2016)

Rad50 promotes ovarian cancer progression through NF‐κB activation
por: Li, Yinuo, et al.
Publicado: (2021)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

RAD51 is essential for spermatogenesis and male fertility in mice
por: Qin, Junchao, et al.
Publicado: (2022)

Replication Stress Induces Micronuclei Comprising of Aggregated DNA Double-Strand Breaks
por: Xu, Bing, et al.
Publicado: (2011)

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
por: Ding, Liya, et al.
Publicado: (2018)

Berberine Radiosensitizes Human Esophageal Cancer Cells by Downregulating Homologous Recombination Repair Protein RAD51
por: Liu, Qiao, et al.
Publicado: (2011)

PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

Cul4a promotes zebrafish primitive erythropoiesis via upregulating scl and gata1 expression
por: Yang, Fan, et al.
Publicado: (2019)

CUL4B promotes replication licensing by up-regulating the CDK2–CDC6 cascade
por: Zou, Yongxin, et al.
Publicado: (2013)

Integrated analysis of long noncoding RNAs and mRNAs reveals their potential roles in the pathogenesis of uterine leiomyomas
por: Guo, Haiyang, et al.
Publicado: (2014)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

PARP1 Inhibitors: antitumor drug design
por: Malyuchenko, N. V., et al.
Publicado: (2015)

S113R mutation in SLC33A1 leads to neurodegeneration and augmented BMP signaling in a mouse model
por: Liu, Pingting, et al.
Publicado: (2017)

Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells
por: Liu, Yugang, et al.
Publicado: (2015)

RECQL4 regulates DNA damage response and redox homeostasis in esophageal cancer
por: Lyu, Guosheng, et al.
Publicado: (2021)

TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
por: Qi, Gonghua, et al.
Publicado: (2021)

Autophagic Flux Unleashes GATA4-NF-κB Axis to Promote Antioxidant Defense-Dependent Survival of Colorectal Cancer Cells under Chronic Acidosis
por: Liu, Xiaojie, et al.
Publicado: (2021)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells
por: El Naggar, Olivia, et al.
Publicado: (2022)

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
por: Garg, Vikas, et al.
Publicado: (2023)

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
por: de Koning, Leanne, et al.
Publicado: (2019)

Ablation of ORMDL3 impairs adipose tissue thermogenesis and insulin sensitivity by increasing ceramide generation
por: Song, Yu, et al.
Publicado: (2021)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
por: Lu, Zhen, et al.
Publicado: (2022)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i1ru8geicnvhr7janc132b7p58